Perindopril treatment for congestive heart failure

  • Edmund H Sonnenblick
    Address for reprints: Edmund H. Sonnenblick, MD, Division of Cardiology, Albert Einstein College of Medicine, 1825 Eastchester Road, Bronx, New York 10461
    Division of Cardiology, Albert Einstein College of Medicine, Bronx, New York, USA
    Search for articles by this author


      Congestive heart failure (CHF) is the most common and lethal consequence of atherosclerotic cardiovascular disease, with a prevalence estimated between 1% and 10%, and very high associated mortality. Preventing the continued progression of established heart failure and improving the prognosis for patients with this disease is difficult, but angiotensin-converting enzyme (ACE) inhibitors have been shown to be effective in reducing mortality in patients with CHF. In a review of the worldwide literature of the efficacy and safety of perindopril erbumine for the treatment of patients with CHF, once-daily treatment with this ACE inhibitor was shown to be effective in patients with CHF of all severities. Its use is associated with a low risk of first-dose hypotension and no unwanted effects on blood pressure in normotensive patients. Perindopril also improves arterial compliance and reverses left ventricular hypertrophy in patients with hypertension. It is well tolerated and has no significant effects on heart rate, indexes of renal function, or plasma lipid profile. It also has no clinically significant interactions with other drugs, including digoxin, likely to be taken by patients with CHF.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Kannel W.B
        Hazards, risks, and threats of heart disease from the early stages to symptomatic coronary heart disease and cardiac failure.
        Cardiovasc Drugs Ther. 1997; 11: 199-212
        • Dargie H.J
        • McMurray J.J
        • McDonagh T.A
        Heart failure.
        J Intern Med. 1996; 239: 309-315
        • Konstam M.A
        • Remme W.J
        Treatment guidelines in heart failure.
        Prog Cardiovasc Dis. 1998; 41: 65-72
        • Brook R.D
        • Greenland P
        Role of secondary prevention in congestive heart failure due to coronary artery disease.
        Coron Artery Dis. 1998; 9: 653-658
        • Cleland J.G.F
        • Bristow M.R
        • Erdmann E
        • Remme W.J
        • Swedberg K
        • Waagstein F
        Beta-blocking agents in heart failure.
        Eur Heart J. 1996; 17: 1629-1639
        • β-Blocker Heart Attack Trial Research Group
        A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results.
        JAMA. 1982; 247: 1707-1714
        • Goldstein S
        The β-Blocker Heart Attack Trial in perspective.
        Cardiology. 1983; 70: 255-262
        • Gundersen T
        • Abrahamsen A.M
        • Kjekshus J
        • Rønnevik P.K
        • Norwegian Multicentre Study Group
        Timolol-related reduction in mortality and reinfarction in patients ages 65-75 years surviving acute myocardial infarction.
        Circulation. 1982; 66: 1179-1184
        • Hjalmarson Å
        • Herlitz J
        • Holmberg S
        • Ryden L
        • Swedberg K
        • Vedin A
        • Waagstein F
        • Waldstrom A
        • Waldstrom J
        • Wedel H
        • Wilhelmsen L
        • Wilhemsson C
        The Göteborg Metoprolol trial.
        Circulation. 1983; 67: I26-I32
        • Herlitz J
        • Hjalmarson Å
        • Swedberg K
        • Ryden L
        • Waagstein F
        Effects on mortality during five years after early intervention with metoprolol in suspected acute myocardial infarction.
        Acta Med Scand. 1988; 223: 227-231
        • Hjalmarson Å
        Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period.
        Am J Cardiol. 1997; 80: 35J-39J
        • Herlitz J
        • Waagstein F
        • Lindqvist J
        • Swedberg K
        • Hjalmarson Å
        Effect of metoprolol on the prognosis for patients with suspected acute myocardial infarction and indirect signs of congestive heart failure (a subgroup analysis of the Göteborg Metoprolol Trial).
        Am J Cardiol. 1997; 80: 40J-44J
        • Waagstein F
        • Bristow M.R
        • Swedberg K
        • Camerine F
        • Fowler M.B
        • Silver M.A
        • Gilbert E.M
        • Johnson M.R
        • Goss F.G
        • Hjalmarson Å
        • Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group
        Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.
        Lancet. 1993; 342: 1441-1446
        • Vanderhoff B.T
        • Ruppel H.M
        • Amsterdam P.B
        Am Acad Fam Physicians. 1998; 58: 1627-1634
        • Australia-New Zealand Heart Failure Research Collaborative Group
        Effects of carvedilol, a vasodilator-β-blocker, in patients with congestive heart failure due to ischemic heart disease.
        Circulation. 1995; 92: 212-218
        • Packer M
        • Bristow M.R
        • Cohn J.N
        • Colucci W.S
        • Fowler M.B
        • Gilbert E.M
        • Shusterman N.H
        • US Carvedilol Heart Failure Study Group
        The effect of carvedilol on morbidity and morality in patients with chronic heart failure.
        N Engl J Med. 1996; 334: 1349-1355
        • Australia/New Zealand Heart Failure Research Collaborative Group
        Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischaemic heart disease.
        Lancet. 1997; 349: 375-380
        • CIBIS-II Investigators and Committees
        The cardiac insufficiency bisoprolol study II (CIBIS-II).
        Lancet. 1999; 353: 9-13
        • Massie B.M
        15 years of heart-failure trials.
        Lancet. 1998; 352: 29-33
        • Krukemyer J.J
        Use of beta-adrenergic blocking agents in congestive heart failure.
        Clin Pharmacol. 1990; 9: 853-863
        • Hjalmarson Å
        • Goldstein S
        • Fagerberg B
        • Wedel H
        • Waagstein F
        • Kjekshus J
        • Wikstrand J
        • El Allaf D
        • Vitovec J
        • Aldershvile J
        • et al.
        • MERIT-HF Study Group
        Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure.
        JAMA. 2000; 283: 1295-1302
        • Hjalmarson A
        • Fagerberg B
        MERIT-HF mortality and morbidity data.
        Basic Res Cardiol. 2000; 95: I-98-I-103
        • Teerlink J.R
        Neurohumoral mechanisms in heart failure.
        J Cardiovasc Pharmacol. 1996; 27: S1-S8
        • CONSENSUS Trial Study Group
        Effects of enalapril on mortality in severe congestive heart failure.
        N Engl J Med. 1987; 316: 1429-1435
        • Swedberg K
        • Kjekshus J
        Effects of enalapril on mortality in severe congestive heart failure.
        Am J Cardiol. 1988; 62: 60A-66A
        • Pfeffer M.A
        • Braunwald E
        • Moyé L.A
        • Basta L
        • Brown E.J
        • Cuddy T.E
        • Davis B.R
        • Geltman E.M
        • Goldman S
        • Flaker G.C
        • et al.
        • SAVE Investigators
        Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the Survival and Ventricular Enlargement Trial.
        N Engl J Med. 1992; 327: 669-677
        • SOLVD Investigators
        Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.
        N Engl J Med. 1991; 325: 293-302
        • SOLVD Investigators
        Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions.
        N Engl J Med. 1992; 327: 685-691
        • Garg R
        • Yusuf S
        • Collaborative Group on ACE Inhibitor Trial
        Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure.
        JAMA. 1995; 273: 1450-1456
        • Givertz M.M
        • Colucci W.S
        New targets for heart-failure therapy.
        Lancet. 1998; 352: 34-38
        • Mancini G.B
        Long-term use of angiotensin-converting enzyme inhibitors to modify endothelial dysfunction.
        Clin Invest Med. 2000; 23: 144-161
        • Blaufarb I.S
        • Sonnenblick E.H
        The renin-angiotensin system in left ventricular remodeling.
        Am J Cardiol. 1996; 77: 8C-16C
        • Cheng J.W
        • Ngo M.N
        Current perspective on the use of angiotensin-converting enzyme inhibitors in the management of coronary (atherosclerotic) artery disease.
        Am Pharmacother. 1997; 31: 1499-1506
        • Rabbani R
        • Topol E.J
        Strategies to achieve coronary arterial plaque stabilization.
        Cardiovasc Res. 1999; 41: 402-417
        • Mancini G.B
        Role of angiotensin-converting enzyme inhibition in reversal of endothelial dysfunction in coronary artery disease.
        Am J Med. 1998; 105: 40S-47S
        • Bounhoure J.P
        • Bottineau G
        • Lechat P
        • Garnham J
        • Lapeyre G
        Value of perindopril in the treatment of chronic congestive heart failure.
        Clin Exp Theory Pract. 1989; A11: 575-586
        • Lechat P
        • Garnham S.P
        • Desche P
        • Bounhoure J.-P
        Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure.
        Am Heart J. 1993; 126: 798-806
        • Flammang D
        • Waynberger M
        • Chassing A
        Acute and long-term efficacy of perindopril in severe chronic congestive heart failure.
        Am J Cardiol. 1993; 71: 48E-56E
        • DiBianco R
        ACE inhibitors in the treatment of heart failure.
        Clin Cardiol. 1990; 13: VII-32-VII-38
        • Navookarasu N.T
        • Rahman A.R
        • Abdullah I
        First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac failure.
        Int J Clin Pract. 1999; 53: 25-30
        • Haı̈at R
        • Piot O
        • Gallois H
        • Hanania G
        Blood pressure response to the first 36 hours of heart failure therapy with perindopril versus captopril.
        J Cardiovasc Pharmacol. 1999; 33: 953-959
        • Richer C
        • Thuillez C
        • Giudicelli J.F
        Perindopril, converting enzyme blockade, and peripheral arterial hemodynamics in the healthy volunteer.
        J Cardiovasc Pharmacol. 1987; 9: 94-102
        • Plante G.E
        The blood vessel as a target organ in hypertension.
        Can J Cardiol. 1994; 10: 25D-29D
        • Asmar R.G
        • Journo H.J
        • Lacolley P.J
        • Santoni J.P
        • Billaud E
        • Levy B.I
        • Safar M.E
        Treatment for one year with perindopril.
        J Hypertens. 1988; 6: S33-S39
        • Sihm I
        • Schroeder A.P
        • Aalkjær C
        • Holm M
        • Mørn B
        • Mulvany M
        • Thygesen K
        • Lederballe O
        Normalization of structural cardiovascular changes during antihypertensive treatment with a regimen based on the ACE-inhibitor perindopril.
        Blood Press. 1995; 4: 241-248
        • Revel F
        • Gallois H
        • Le Coz Y
        • Richard R
        • Ollivier J.P
        Évolution de la masse ventriculaire gauche dans une population de 893 hypertendus.
        Ann Cardiol Angeiol. 1994; 43: 594-599
        • Schulte K.-L
        • Meyer-Sabellek W
        • Liederwald K
        • van Gemmeren D
        • Lenz T
        • Gotzen R
        Relation of regression of left ventricular hypertrophy to changes in ambulatory blood pressure after long-term therapy with perindopril versus nifedipine.
        Am J Cardiol. 1992; 70: 468-473
        • Hui Y
        • Dai Z
        • Chen X
        • Wang W
        Effect of perindopril and metoprolol on left ventricular hypertrophy and performance in essential hypertension.
        Chin Med J. 1995; 108: 678-681
        • Yan L
        • Yang R
        • Cheng H
        • Fu Z
        • Zhong G
        • Yan T
        Protective effect of the angiotensin-converting enzyme inhibitor perindopril on diabetic glomerulopathy in streptozotocin-induced diabetic rats.
        Chin Med J. 1998; 111: 306-308
        • Grandi A.M
        • Bignotti M
        • Gaudio G
        • Zanzi P
        • Gausti L
        • Venco A
        Ambulatory blood pressure and left ventricular changes during antihypertensive treatment.
        J Cardiovasc Pharmacol. 1995; 26: 737-741
        • Richard C
        • Thuillez C
        • Depret J
        • Auzépy P
        • Giudicelli J.-F
        Regional hemodynamic effects of perindopril in congestive heart failure.
        Am Heart J. 1993; 126: 782-788
        • Thuillez C
        • Richard C
        • Richer C
        • Loueslati H
        • Perret L
        • Auzépy P
        • Giudicelli J.-F
        Peripheral haemodynamic effects of perindopril compared in patients with congestive heart failure and in normal volunteers.
        J Hypertens. 1988; 6: S41-S43
        • Thuillez C
        • Richard C
        • Loueslati H
        • Auzepy P
        • Giudicelli J.F
        Systemic and regional hemodynamic effects of perindopril in congestive heart failure.
        J Cardiovasc Pharmacol. 1990; 15: 527-535
        • Desche P
        • Antony I
        • Lerebours G
        • Violet I
        • Robert S
        • Weber C
        Acceptability of perindopril in mild-to-moderate chronic congestive heart failure.
        Am J Cardiol. 1993; 71: 61E-68E
        • Brichard S
        • Lambert A.E
        Perindopril safety and tolerance in at-risk patients.
        Drugs. 1990; 39: 64-70
        • Chau W.L
        • Burnett Jr, J.C
        Treatment of congestive heart failure in the elderly.
        Coron Artery Dis. 1997; 8: 505-509
        • Suter P.M
        • Vetter W
        Metabolic effects of antihypertensive drugs.
        J Hypertens. 1995; 13: S11-S17
        • Middeke M
        • Krone W
        Effects of perindopril on serum lipids in hypertensive patients with hyperlipidemia.
        J Cardiovasc Pharmacol. 1994; 23: 629-631
        • Vandenburg M.J
        • Stephens J.D
        • Resplandy G
        • Dews I.M
        • Robinson J
        • Desche P
        Digoxin pharmacokinetics and perindopril in heart failure patients.
        J Clin Pharmacol. 1993; 33: 146-149
        • Elisaf M.S
        • Theodorou J
        • Pappas H
        • Papagalanis N
        • Katopodis K
        • Kalaitzidis R
        • Siamopoulos K.C
        Effectiveness and metabolic effects of perindopril and diuretics combination in primary hypertension.
        J Hum Hypertens. 1999; 13: 787-791
        • Chrysant S.G
        Perindopril/hydrochlorothiazide dose combinations for the treatment of hypertension.
        J Clin Pharmacol. 1997; 37: 47-52
        • Tan K.W
        • Leenen F.H
        Persistence of anti-hypertensive effect after missed dose of perindopril.
        Br J Clin Pharmacol. 1999; 48: 628-630
        • Fox K.M
        • Henderson J.R
        • Bertrand M.E
        • Ferrari R
        • Remme W.J
        • Simoons M.L
        The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA).
        Eur Heart J. 1998; 19: J52-J55